{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:38:55Z","timestamp":1779881935965,"version":"3.53.1"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"\n Background:<\/jats:title>\n Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR.<\/jats:p>\n <\/jats:sec>\n \n Objectives:<\/jats:title>\n To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients.<\/jats:p>\n <\/jats:sec>\n \n Design:<\/jats:title>\n Systematic review and meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Data sources and methods:<\/jats:title>\n A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life\u2013Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS\u2009+\u20097), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), \u221218.79; 95% CI, \u221222.32 to \u221215.25;\n p<\/jats:italic>\n \u2009<\u20090.00001;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200928%) and mNIS\u2009+\u20097 scores (MD, \u221226.90; 95% CI, \u221231.67 to \u221222.13;\n p<\/jats:italic>\n \u2009<\u20090.00001;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200961%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64\u2013139.32;\n p<\/jats:italic>\n \u2009<\u20090.00001;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200959%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69\u20131.15;\n p<\/jats:italic>\n \u2009=\u20090.36;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200934%), serious adverse effects (RR, 0.70; 95% CI, 0.31\u20131.58;\n p<\/jats:italic>\n \u2009=\u20090.39;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200920%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58;\n p<\/jats:italic>\n \u2009=\u20090.39;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200920%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs.<\/jats:p>\n <\/jats:sec>\n \n Trial registration:<\/jats:title>\n PROSPERO (CRD42024568346).<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/17539447251390782","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:55:39Z","timestamp":1762955739000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8753-6681","authenticated-orcid":false,"given":"Maha","family":"Sajjad","sequence":"first","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6687-896X","authenticated-orcid":false,"given":"Rabia","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5504-052X","authenticated-orcid":false,"given":"Riya","family":"Bhagwan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8715-9627","authenticated-orcid":false,"given":"Hassan","family":"Ijaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9818-3596","authenticated-orcid":false,"given":"Ayesha","family":"Ejaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hifza","family":"Qadeer ud din","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4018-4385","authenticated-orcid":false,"given":"Amna","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mohsin","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2317-6866","authenticated-orcid":false,"given":"Umaimah","family":"Naeem","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, 3\/16 B Survey #79 Golden town, Wireless gate, Malir, Karachi 75050, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04889-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8064-9"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b18-00625"},{"issue":"6","key":"e_1_3_4_7_2","article-title":"RNA interference therapeutics for hereditary amyloidosis: a narrative review of clinical trial outcomes and future directions","volume":"16","author":"Dave P","year":"2024","unstructured":"Dave P, Anand P, Kothawala A, et al. RNA interference therapeutics for hereditary amyloidosis: a narrative review of clinical trial outcomes and future directions. Cureus 2024; 16(6): e62981.","journal-title":"Cureus"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2993"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.14304\/SURYA.JPR.V4N7.5"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_4_12_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_4_14_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, J Savovi\u0107, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S219979"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28026"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.01.013"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14285"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30368-9"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229681100500326"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12059"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.041"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25563"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27022"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116424"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)31351-8"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010062"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001482"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch10"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447251390782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447251390782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447251390782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T13:17:33Z","timestamp":1763299053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447251390782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"alternative-id":["10.1177\/17539447251390782"],"URL":"https:\/\/doi.org\/10.1177\/17539447251390782","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"17539447251390782"}}